muhammad orri baskoro

Dr. muhammad orri baskoro


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Plasmatology
Verified
Journal Article
Open access
ALAnna Mira Lubis
Anna Mira Lubis
MBmuhammad orri baskoro
muhammad orri baskoro
AYAmirah Yasmin
Amirah Yasmin
Platelet transfusion refractoriness (PTR) is a conditioikb1n where platelet counts fail to increase adequately in several transfusions, often found in hemato-oncological situations. PTR poses life-threatening risks to patients, especially in cases when the platelet is very low, and transfusion is life-saving. It can be differentiated into immune or non-immune causes. While non-immune causes predominate, immune factors, particularly anti-HLA antibodies, are also notable in many cases. Accurately determining if platelet transfusion failure originates from an immune or non-immune cause is vital due to differing treatments, particularly the need for HLA-compatible platelets with immune causes. Yet, a lack of consensus exists regarding the diagnostic methods and treatment modalities. Therefore, this review aims to explore the origins, mechanisms, diagnostic criteria, and management approaches concerning PTR.

7 October 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
MJMuhammad Ade Junaidi
Muhammad Ade Junaidi
FBFilberto Budhy
Filberto Budhy
MHMulki Hakam
Mulki Hakam
BABany Faris Amin
Bany Faris Amin
MBmuhammad orri baskoro
muhammad orri baskoro
Background/Objectives: Recombinant human bone morphogenetic protein-2 (rhBMP-2) is an osteoinductive agent increasingly used in many orthopedic cases such as fracture healing, nonunion, critical-sized bone defects, and limb reconstruction cases. However, its efficacy and safety remain controversial especially regarding its optimal dosing, delivery, and adverse effect concerns. This narrative review aims to summarize the rhBMP-2 evidence in orthopedic trauma and limb reconstruction. Methods: A literature search was conducted on PubMed/MEDLINE, Scopus, and Web of Science up to August 2026. We prioritized meta-analyses, systematic reviews, randomized controlled trials, and clinical studies. Results: rhBMP-2 induces osteogenic differentiation, endochondral ossification, and bone regeneration through canonical Smad-dependent and non-canonical pathways. Current evidence suggests a potential use of rhBMP-2 as an adjunct in selected open fractures, delayed union and nonunion, and complex reconstruction patients, although the results are still heterogeneous. Some studies reported fewer secondary interventions in open tibial fractures, while others failed to reproduce a consistent advantage over standard care or autograft. Hydroxyapatite-based delivery systems have recently demonstrated promising union rates at lower total rhBMP-2 doses, suggesting that the carrier and delivery method may determine the effect. Currently available studies carry clear weaknesses: small samples, few adequately powered trials, heterogeneous indications, no established optimal dose, high cost, and complications that include inflammation and ectopic bone formation. Controlled-release scaffolds, heparin-based microparticles, biomimetic carriers, and gene- or mRNA-based delivery are future research directions currently under investigation. Conclusions: rhBMP-2 is a promising adjunct that may benefit selected high-risk patients, but it does not replace stable fixation, infection control, soft-tissue management, or autologous grafting. Further trials are needed to define appropriate patient selection, the minimum effective dose, and optimal delivery systems.